Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. REVB
stocks logo

REVB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.915
-93.88%
--
--
0.000
-100%
--
--
0.000
-100%
Estimates Revision
The market is revising No Change the revenue expectations for Revelation Biosciences, Inc. (REVB) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -65.16%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-65.16%
In Past 3 Month
Wall Street analysts forecast REVB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REVB is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast REVB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REVB is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.000
sliders
Low
20.00
Averages
20.00
High
20.00
Current: 1.000
sliders
Low
20.00
Averages
20.00
High
20.00
no data image
No Data

Valuation Metrics

The current forward P/E ratio for Revelation Biosciences Inc (REVB.O) is -0.20, compared to its 5-year average forward P/E of -4.41. For a more detailed relative valuation and DCF analysis to assess Revelation Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.41
Current PE
-0.20
Overvalued PE
4.41
Undervalued PE
-13.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.35
Current PS
0.00
Overvalued PS
1.95
Undervalued PS
-1.24
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

REVB News & Events

Events Timeline

(ET)
2025-09-11
08:39:52
Revelation Biosciences Reports $9.6M Raised Through Warrant Exercise
select
2025-09-10 (ET)
2025-09-10
07:26:21
Revelation Biosciences to Host Webcast for Discussion of Phase 1b PRIME Data
select
2025-09-09 (ET)
2025-09-09
08:26:20
Revelation Biosciences Unveils Key Findings from PRIME Study
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-24Newsfilter
Revelation Biosciences Submits FDA Meeting Package for Gemini AKI Treatment
  • FDA Meeting Preparation: Revelation Biosciences has successfully submitted the end-of-phase 1 meeting package for Gemini as a treatment for acute kidney injury, with a meeting scheduled with the FDA later this year. This milestone represents a significant step in the clinical development and regulatory approval pathway, potentially accelerating Gemini's market entry.
  • Clinical Research Progress: The company plans to initiate a later-stage clinical study in 2026 to evaluate Gemini's effectiveness in treating acute kidney injury. This study will provide additional data to support Gemini's clinical applications, further advancing its use in kidney disease treatment.
  • PRIME Study Results: Revelation achieved positive safety and activity data from its Phase 1b PRIME study, demonstrating that Gemini significantly reduces inflammation levels in chronic kidney disease patients. These results lay the groundwork for Gemini's potential applications in acute and chronic inflammatory conditions, enhancing its market competitiveness.
  • Market Demand Context: Acute kidney injury affects over 10% of hospitalized patients, with limited existing treatment options, making the development of Gemini timely to meet this urgent market need. As demand for new therapies rises, Revelation is well-positioned to capture a significant share in the kidney disease treatment sector.
[object Object]
Preview
9.0
11-21Yahoo Finance
Revelation Set to Meet with FDA Later This Year
  • Company Update: Revelation Biosciences (REVB) announced it is preparing for a meeting with the US Food and Drug Administration (FDA).
  • Regulatory Progress: The meeting is part of the company's ongoing efforts to advance its product development and regulatory strategy.
[object Object]
Preview
9.5
08-08Newsfilter
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

  • Financial Performance: Revelation Biosciences reported a net loss of $2.4 million for Q2 2025, an improvement from $8.4 million in the same period last year, with cash reserves of $5.2 million expected to fund operations through December 2025.

  • Clinical Developments: The company completed patient dosing in its PRIME Phase 1b Clinical Study for Gemini, a treatment aimed at reducing inflammation and improving health outcomes in chronic kidney disease patients, with data expected to be announced later this quarter.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Revelation Biosciences Inc (REVB) stock price today?

The current price of REVB is 1 USD — it has increased 4.93 % in the last trading day.

arrow icon

What is Revelation Biosciences Inc (REVB)'s business?

Revelation Biosciences, Inc. is a clinical-stage life sciences company, which is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. The Company's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The Company has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.

arrow icon

What is the price predicton of REVB Stock?

Wall Street analysts forecast REVB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REVB is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Revelation Biosciences Inc (REVB)'s revenue for the last quarter?

Revelation Biosciences Inc revenue for the last quarter amounts to -1.94M USD, increased 8.14 % YoY.

arrow icon

What is Revelation Biosciences Inc (REVB)'s earnings per share (EPS) for the last quarter?

Revelation Biosciences Inc. EPS for the last quarter amounts to -1588901.00 USD, decreased -82.87 % YoY.

arrow icon

What changes have occurred in the market's expectations for Revelation Biosciences Inc (REVB)'s fundamentals?

The market is revising No Change the revenue expectations for Revelation Biosciences, Inc. (REVB) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -65.16%.
arrow icon

How many employees does Revelation Biosciences Inc (REVB). have?

Revelation Biosciences Inc (REVB) has 8 emplpoyees as of December 05 2025.

arrow icon

What is Revelation Biosciences Inc (REVB) market cap?

Today REVB has the market capitalization of 5.92M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free